News
No FDA decision yet on EM 100 treatment for ocular itching.- Eton Pharma + Bausch & Lomb
Eton Pharmaceuticals, Inc reported that its partner, Bausch & Lomb, has not yet received a communication from the FDA regarding its decision on the review of EM 100. EM 100’s Generic Drug User Fee Act (GDUFA) target action date was August 10th. The company is not aware of any information requests outstanding and expects the FDA to communicate a decision in the coming days.
Condition: Conjunctivitis
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins